QTTBQ32 Bio Inc.同业对比
Q32 Bio Inc. 与SIC 2834 行业的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 | 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| QTTB本股 | $262M#8 | 2.8x#3 | 2.5x#11 | 4.9x#3 | — | 162.5%#1 | 31.5%#1 | 28.1%#1 | — | — | — | — |
| MPLT | $290M#1 | 0.1x#1 | 0.8x#3 | — | — | -107.7%#12 | — | -46.3%#7 | — | — | — | — |
| FULC | $287M#2 | — | 0.9x#4 | — | -100.0%#8 | -670.0%#16 | — | -24.1%#4 | — | — | — | — |
| LYEL | $279M#4 | — | 1.2x#5 | 7742.9x#9 | -41.0%#6 | 20.0%#3 | -748344.4%#10 | -117.4%#11 | — | — | — | — |
| CYPH | $280M#3 | 4.1x#4 | 2.0x#8 | 186.4x#8 | 0.0%#5 | 107.4%#2 | -2737.8%#9 | 3.6%#2 | — | — | — | — |
| BIOA | $274M#5 | — | 0.7x#1 | 30.4x#4 | — | -13.4%#7 | -1031.5%#5 | -21.5%#3 | — | — | — | — |
| RCKT | $270M#6 | — | 0.7x#2 | — | — | 13.8%#5 | — | -60.5%#9 | — | — | -30.9%#2 | — |
| ARCT | $265M#7 | — | 1.5x#6 | 3.2x#2 | -46.1%#7 | 18.7%#4 | -93.0%#3 | -38.3%#5 | -136.2%#3 | — | 0.3%#1 | — |
| LRMR | $261M#9 | — | 2.1x#9 | — | — | -105.5%#11 | — | -130.1%#12 | -350.3%#5 | — | — | — |
| BCYC | — | — | — | — | 105.8%#3 | -29.5%#8 | -340.4%#4 | -43.3%#6 | -372.9%#6 | — | — | — |
| GLSI | $253M#10 | — | 81.0x#13 | — | — | -11.2%#6 | — | -621.1%#13 | — | — | — | — |
| CAMP | $245M#11 | — | — | 70.1x#7 | 436.5%#1 | -55.2%#10 | -1502.4%#6 | — | — | — | — | — |
| ABEO | $244M#12 | — | 1.9x#7 | 42.0x#6 | — | -211.7%#14 | -1536.9%#7 | -55.6%#8 | -121.6%#2 | — | — | — |
| LFCR | $244M#13 | — | — | 1.9x#1 | 0.5%#4 | -422.5%#15 | -13.4%#2 | — | -28.7%#1 | 3#1 | — | — |
| KRRO | $240M#14 | — | 2.3x#10 | 37.6x#5 | 181.5%#2 | -40.3%#9 | -1906.4%#8 | -113.6%#10 | -155.2%#4 | — | — | — |
| GTBP | $234M#15 | 1.0x#2 | 65.5x#12 | — | — | -115.4%#13 | — | -794.5%#14 | — | — | — | 0.1%#1 |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 本表构建超时,仅覆盖该组的一部分成员;排名仅相对于已列出的行,稍后会自动补全。 数据构建于 2026-11-03。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议